Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of novel drugs and diagnostic products for the aging population. The company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. Its lead drug candidate is NX-1207, which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as completed a Phase II clinical trial for low grade localized prostate cancer. The company also has other drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas. It markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Saint Laurent, Canada.